

Figure 1

Figure 2




Figure 3




Figure 4




Figure 5




Figure 6






Figure 7




**Figure 8.** Mean Nelfinavir Plasma Concentration-Time Profiles Following Administration of 5 x 250-mg Nelfinavir Tablets to Fasting Subjects (filled circles), During a Moderate Calorie/Low Fat Meal (open circles), and During a Moderate Calorie/High Fat Meal (filled squares) (Study A4301009). Upper and lower panels are linear and semi-logarithmic plots, respectively.






**Figure 9.** Individual Nelfinavir Cmax (upper panel) and AUC(0-∞) Values (lower panel) Following Administration of 5 x 250-mg Nelfinavir Tablets to Fasting Subjects, During a Moderate Calorie/Low Fat Meal, and During a Moderate Calorie/High Fat Meal (Study A4301009). Individual and mean values are represented by open circles and triangles, respectively.



**Figure 10.** Mean M8 Plasma Concentration-Time Profiles Following Administration of 5 x 250-mg Nelfinavir Tablets to Fasting Subjects (filled circles), During a Moderate Calorie/Low Fat Meal (open circles), and During a Moderate Calorie/High Fat Meal (filled squares) (Study A4301009). Upper and lower panels are linear and semi-logarithmic plots, respectively.



**Figure 11. Individual M8 Cmax (upper panel) and AUC(0-∞) Values (lower panel) Following Administration of 5 x 250-mg Nelfinavir Tablets to Fasting Subjects, During a Moderate Calorie/Low Fat Meal, and During a Moderate Calorie/High Fat Meal (Study A4301009). Individual and mean values are represented by open circles and triangles, respectively.**